AstraZeneca roars to greater heights
Cambridge biopharma company AstraZeneca has delivered a thumping set of H1 and Q2 2024 results with all key metrics heading north. Total revenue was up 18 per cent to $25,617 million, driven by an 18 per cent increase in product sales and continued growth in alliance revenue from partnered medicines.